Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Por:
Cebrian A, del Pulgar T, Mendez-Vidal M, Gonzalvez M, Lainez N, Castellano D, Garcia-Carbonero I, Esteban E, Saez M, Villatoro R, Suarez C, Carrato A, Munarriz-Ferrandiz J, Basterrechea L, Garcia-Alonso M, Gonzalez-Larriba J, Perez-Valderrama B, Cruz-Jurado J, del Alba A, Moreno F, Reynes G, Rodriguez-Remirez M, Boni V, Mahillo-Fernandez I, Martin Y, Viqueira A, Garcia-Foncillas J
Publicada:
24 ene 2017
Resumen:
Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this study was to analyze single nucleotide polymorphisms (SNPs) in genes linked to mode of action of sunitinib and immune response as biomarkers for mRCC. This is a multicenter, prospective and observational study involving 20 hospitals. Seventy-five mRCC patients treated with sunitinib as first line were used to assess the impact of 63 SNPs in 31 candidate genes on clinical outcome. rs2243250 (IL4) and rs5275 (PTGS2) were found to be significantly associated with shorter cancer-specific survival (CSS). Moreover, allele C (rs5275) was associated with higher PTGS2 expression level confirming its functional role. Combination of rs5275 and rs7651265 or rs2243250 for progression free survival (PFS) or CSS, respectively, was a more valuable predictive biomarker remaining significant after correction for multiple testing. It is the first time that association of rs5275 with survival in mRCC patients is described. Two-SNP models containing this functional variant may serve as more predictive biomarkers for sunitinib and could suppose a clinically relevant tool to improve the mRCC patient management.
Filiaciones:
Cebrian A:
Fdn Jimenez Diaz Univ Hosp, Madrid, Spain
del Pulgar T:
Fdn Jimenez Diaz Univ Hosp, Madrid, Spain
Mendez-Vidal M:
Reina Sofia Univ Hosp, Cordoba, Spain
Gonzalvez M:
Virgen de la Arrixaca Univ Hosp, Murcia, Spain
Lainez N:
Complejo Hosp Navarra, Pamplona, Spain
Castellano D:
12 Octubre Univ Hosp, Madrid, Spain
Garcia-Carbonero I:
Virgen Salud Univ Hosp, Toledo, Spain
Esteban E:
Cent Univ Hosp Asturias, Oviedo, Spain
Saez M:
Virgen de la Victoria Univ Hosp, Malaga, Spain
Villatoro R:
Hosp Costa del Sol, Marbella, Spain
Suarez C:
Vall dHebron Univ Hosp, Barcelona, Spain
Carrato A:
Ramon y Cajal Univ Hosp, Madrid, Spain
Munarriz-Ferrandiz J:
Hosp Prov Castellon, Castellon de La Plana, Spain
Basterrechea L:
Hosp Donostia, San Sebastian, Spain
Garcia-Alonso M:
Insular Gran Canaria Univ Hosp, Islas Canarias, Spain
Gonzalez-Larriba J:
Clin San Carlos Univ Hosp, Madrid, Spain
Perez-Valderrama B:
Virgen del Rocio Univ Hosp, Seville, Spain
Cruz-Jurado J:
Canarias Univ Hosp, Santa Cruz De Tenerife, Islas Canarias, Spain
del Alba A:
Son Espases Univ Hosp, Palma De Mallorca, Spain
Moreno F:
Fuenlabrada Univ Hosp, Fuenlabrada, Spain
Reynes G:
La Fe Univ Hosp, Valencia, Spain
Rodriguez-Remirez M:
Fdn Jimenez Diaz Univ Hosp, Madrid, Spain
Boni V:
Ctr Appl Med Res, Pamplona, Spain
Mahillo-Fernandez I:
Fdn Jimenez Diaz Univ Hosp, Madrid, Spain
Martin Y:
Trial Form Support, Madrid, Spain
Viqueira A:
Pfizer Oncol, Madrid, Spain
Garcia-Foncillas J:
Fdn Jimenez Diaz Univ Hosp, Madrid, Spain
|